FDA Issues Temporary Guidance on Resuming Normal Drug Manufacturing

The FDA is urging drugmakers to develop a “resumption plan” to help them prioritize as they get back to normal operations and resume current good manufacturing practice (CGMP) activities that were modified or delayed due to COVID-19.
Source: Drug GMP Report